TERMINATION AGREEMENT OF THE CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENTTermination Agreement • March 22nd, 2023 • Context Therapeutics Inc. • Pharmaceutical preparations
Contract Type FiledMarch 22nd, 2023 Company IndustryThis TERMINATION AGREEMENT OF THE CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this “Agreement”), made as of 21 March 2023 (the “Termination Effective Date”), is by and between Context Therapeutics Inc., having a place of business at 2001 Market Street, Suite 3915, Unit# 15, Philadelphia, PA 19103 USA (“Context”), and Berlin-Chemie AG - Menarini Group, having a place of business at Glienicker Weg 125,12489 Berlin, Germany (“Menarini”). Context and Menarini are each referred to herein individually as a “Party” and collectively the “Parties”.
AMENDMENT 1 TO RESEARCH COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • March 22nd, 2023 • Context Therapeutics Inc. • Pharmaceutical preparations
Contract Type FiledMarch 22nd, 2023 Company IndustryTHIS AMENDMENT 1 TO RESEARCH COLLABORATION AND LICENSE AGREEMENT (“Amendment”), is entered into as of the 20 day of March, 2023 (“Effective Date”) by and between Integral Molecular, Inc. a Delaware corporation (“Integral”), and Context Therapeutic, LLC, a Delaware limited liability company (“Context”). Integral and Context may each be referred to herein as a “Party” and collectively, the “Parties”.